These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21994861)

  • 1. Prescribing medications in patients with decompensated liver cirrhosis.
    Amarapurkar DN
    Int J Hepatol; 2011; 2011():519526. PubMed ID: 21994861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug administration in chronic liver disease.
    Westphal JF; Brogard JM
    Drug Saf; 1997 Jul; 17(1):47-73. PubMed ID: 9258630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: prescribing medications in patients with cirrhosis - a practical guide.
    Lewis JH; Stine JG
    Aliment Pharmacol Ther; 2013 Jun; 37(12):1132-56. PubMed ID: 23638982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose adjustment in patients with liver disease.
    Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
    Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.
    Weersink RA; Bouma M; Burger DM; Drenth JP; Hunfeld NG; Kranenborg M; Monster-Simons MH; van Putten SA; Metselaar HJ; Taxis K; Borgsteede SD
    BMJ Open; 2016 Oct; 6(10):e012991. PubMed ID: 27733414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
    Morgan DJ; McLean AJ
    Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A guide to the management of tuberculosis in patients with chronic liver disease.
    Dhiman RK; Saraswat VA; Rajekar H; Reddy C; Chawla YK
    J Clin Exp Hepatol; 2012 Sep; 2(3):260-70. PubMed ID: 25755442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Pose E; Napoleone L; Amin A; Campion D; Jimenez C; Piano S; Roux O; Uschner FE; de Wit K; Zaccherini G; Alessandria C; Angeli P; Bernardi M; Beuers U; Caraceni P; Durand F; Mookerjee RP; Trebicka J; Vargas V; Andrade RJ; Carol M; Pich J; Ferrero J; Domenech G; Llopis M; Torres F; Kamath PS; Abraldes JG; Solà E; Ginès P
    Lancet Gastroenterol Hepatol; 2020 Jan; 5(1):31-41. PubMed ID: 31607677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic dosing in cirrhosis.
    Halilovic J; Heintz BH
    Am J Health Syst Pharm; 2014 Oct; 71(19):1621-34. PubMed ID: 25225448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing in patients with abnormal liver function tests.
    Smith E; Desmond P
    Aust Fam Physician; 2013; 42(1-2):30-3. PubMed ID: 23529456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative Care of Patients With Liver Cirrhosis: A Review.
    Abbas N; Makker J; Abbas H; Balar B
    Health Serv Insights; 2017; 10():1178632917691270. PubMed ID: 28469455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.
    Schlatter C; Egger SS; Tchambaz L; Krähenbühl S
    Drug Saf; 2009; 32(7):561-78. PubMed ID: 19530743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
    Johnson TN; Boussery K; Rowland-Yeo K; Tucker GT; Rostami-Hodjegan A
    Clin Pharmacokinet; 2010 Mar; 49(3):189-206. PubMed ID: 20170207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safe use of proton pump inhibitors in patients with cirrhosis.
    Weersink RA; Bouma M; Burger DM; Drenth JPH; Harkes-Idzinga SF; Hunfeld NGM; Metselaar HJ; Monster-Simons MH; van Putten SAW; Taxis K; Borgsteede SD
    Br J Clin Pharmacol; 2018 Aug; 84(8):1806-1820. PubMed ID: 29688583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of newer antibacterial agents in liver disease.
    Westphal JF; Brogard JM
    Clin Pharmacokinet; 1993 Jan; 24(1):46-58. PubMed ID: 8448972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a transjugular intrahepatic portosystemic shunt combined with autologous bone marrow cell infusion in patients with decompensated liver cirrhosis: an exploratory study.
    Huang M; Feng Z; Ji D; Cao Y; Shi X; Chen P; Wang P; Tang M; Liu K
    Cytotherapy; 2014 Nov; 16(11):1575-1583. PubMed ID: 25287603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.
    Benmassaoud A; Freeman SC; Roccarina D; Plaz Torres MC; Sutton AJ; Cooper NJ; Iogna Prat L; Cowlin M; Milne EJ; Hawkins N; Davidson BR; Pavlov CS; Thorburn D; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD013123. PubMed ID: 31978257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.